جستجوی استاد راهنمای دانشگاهی

Youngjae Youمشاهده پروفایل

استاد

• Antibody-Drug Conjugates
• Cancer Chemotherapy
• Medicinal Chemistry
• +۳ مورد دیگر

Youngjae You is a Professor of Empire Innovation in the Department of Pharmaceutical Sciences at the University at Buffalo School of Pharmacy. His research focuses on Antibody-Drug Conjugates, Cancer Chemotherapy, Medicinal Chemistry, and Targeted Drug Delivery. He holds adjunct roles at the University of Oklahoma Health Sciences Center and has led numerous grants totaling over $10 million in funding. Key awards include the 2019 Professor of Empire Innovation title and multiple DoD/CDMRP grants. His work emphasizes prodrug design, photodynamic therapy, and combination therapies. Education : PhD in Pharmaceutical Chemistry, Chungnam National University (2001) MS in Pharmaceutical Chemistry, Chungnam National University (2000) BPharm, Chungnam National University (1994) Research Interests : Dr. You specializes in developing light-activatable prodrugs for targeted cancer therapies, including far-red/NIR light-activated delivery systems. His work integrates quantitative pharmacokinetic modeling, singlet oxygen dynamics, and receptor-targeted drug conjugation to enhance therapeutic efficacy while minimizing off-target effects. Key applications include bladder, breast, and ovarian cancers. Funding Highlights : NIH/NIGMS: $1.37M (2023-2027) for light-responsive drug delivery National Cancer Institute: $2.1M (2022-2027) for bladder cancer treatments DoD/CDMRP/PRCRP: $392K (2017-2020) for photodynamic-chemotherapy combinations Awards : PHF Presidential Professorship (2018) American Cancer Society Research Scholar Grant (2013) Multiple DoD/CDMRP Idea Awards Service & Grants : Serves as Principal Investigator on 8 major grants. Active reviewer for Wellcome Trust, NIH, and international funding agencies. Holds patents on BODIPY derivatives and singlet oxygen-labile linkers. Lab & Collaborations : Leads the You Lab at UB, collaborating with bioengineers and clinicians to advance photomedicine and targeted drug delivery systems. Engaged in multidisciplinary teams addressing spatiotemporal control in cancer treatments.

• Neural Interfaces
• Micro/Nano Electro Mechanical Systems (MEMS)
• Biosystems & Computational Biology
• +۳ مورد دیگر

Michel M. Maharbiz is a Professor in the Department of Electrical Engineering and Computer Science at the University of California, Berkeley. He leads research on miniaturized bioelectronic interfaces, including neural dust implants and cyborg insects. He holds affiliations with the Berkeley Sensor & Actuator Center (BSAC), Center for Neural Engineering & Prostheses (CNEP), and SWARM Lab. His education includes a Ph.D. in EECS from UC Berkeley (2003) and a B.S. in EE from Cornell University (1997). Maharbiz's research integrates MEMS, ultrasonic systems, and synthetic biology to develop wireless neural interfaces, implantable sensors, and biohybrid devices. Key focus areas are neural dust technology for peripheral nerve recording, magnetoelastic strain sensors for medical applications, and electrochemical biosensing using bacterial flagellar motors. His publications emphasize neural interfaces, ultrasonic implants, and biomedical monitoring. Recent articles explore ultrasonic power delivery (2025), radiation detectors for oncology (2025), and fracture-healing smart plates (2019). Trends include miniaturization of wireless implants, closed-loop therapeutic systems, and novel biomaterials. Scientific Awards: McKnight Technological Innovations in Neuroscience Award (2017) Chan-Zuckerberg Biohub Investigator (2017) NSF CAREER Award (2009) MIT TR10 Top Emerging Technology (2009) Bakar Fellows Spark Award (2012) He directs the Maharbiz Lab, advancing neural dust and bioelectronic interfaces. Projects include impedance-based fracture monitoring, carbon fiber neural arrays, and hernia repair sensors. Funding includes NSF and industry partnerships for implantable device development.

Martin T. Wellsمشاهده پروفایل

استاد

• Applied Statistics
• Theoretical Statistics
• Bayesian Statistics
• +۷ مورد دیگر

Martin T. Wells is the Charles A. Alexander Professor of Statistical Sciences at Cornell University, with joint appointments in the Department of Statistical Science, Department of Biological Statistics and Computational Biology, Department of Social Statistics, and as Professor of Clinical Epidemiology and Health Services Research at Weill Medical School. He serves as Editor-in-Chief of the ASA-SIAM Book Series and Co-Editor of the Journal of Empirical Legal Studies. Cornell University, Ithaca, NY Weill Cornell Medical College Research Interests span applied and theoretical statistics, Bayesian methods, biostatistics, clinical epidemiology, and computational biology. His work bridges disciplines like finance, legal studies, and health services research. Article Trends highlight advancements in Bayesian modeling, quantum cognition machine learning, tensor analysis, and misclassification correction, with applications in genomics, finance, and public health. Fellow of the American Statistical Association Fellow of the Royal Statistical Society Contributions include developing statistical software (e.g., rTensor), methodological innovations in clinical trials, and empirical legal studies on civil rights and the death penalty.

Aleksandar Jeremicمشاهده پروفایل

دانشیار

• Biomedical Signal Processing
• Statistical Signal Processing
• Biometrics
• +۷ مورد دیگر

Aleksandar Jeremic is an Associate Professor in both the Electrical & Computer Engineering department and the McMaster School of Biomedical Engineering at McMaster University. His research focuses on biomedical signal processing, statistical signal processing, and biometrics, with applications in healthcare and biomedical systems. He holds a Dipl. Ing. from the University of Belgrade, and an M.S. and Ph.D. from the University of Illinois at Chicago. His expertise spans physiological signal analysis (e.g., ECG/EEG), medical imaging, and machine learning for biomedical applications. He has authored over 50 technical articles and two book chapters, and has been recognized with a teaching award from the McMaster Electrical and Computer Engineering Society (2018). He supervises graduate students in both theoretical and applied research areas. Dr. Jeremic teaches advanced courses such as Biomedical Signal Modeling and Processing and Advanced Probability and Random Processes , emphasizing practical applications of signal processing in healthcare. His work includes clinical implementations like neonatal seizure monitoring software and microwave imaging for breast cancer detection.

• Lymphoma
• Hodgkin Lymphoma
• Non-Hodgkin Lymphoma
• +۵ مورد دیگر

Jonathan W. Friedberg, M.D., M.M.Sc. is the Director of the Wilmot Cancer Institute and Professor in the Department of Medicine, Hematology/Oncology at the University of Rochester School of Medicine and Dentistry. He holds the Samuel E. Durand Chair in Medicine and leads one of the nation's premier lymphoma programs. Dr. Friedberg is internationally recognized for his expertise in lymphoma treatment, particularly in developing novel therapies and clinical trial approaches. Dr. Friedberg's research focuses on lymphoma, with particular expertise in Hodgkin lymphoma, non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, and chronic lymphocytic leukemia. His work spans the entire treatment continuum from diagnosis through novel therapies including autologous stem cell transplantation and CAR-T cell interventions. He has built a comprehensive lymphoma program with expertise spanning hematopathology, radiation oncology, dermatology, and neurology, in addition to hematology and medical oncology. His research interests include developing risk-adapted treatment strategies, investigating novel therapeutic agents, and improving outcomes for patients with various lymphoma subtypes. Dr. Friedberg's extensive publication record demonstrates his leadership in lymphoma research, with recent work focusing on immunotherapy combinations, predictive modeling, risk stratification, and novel treatment approaches for various lymphoma subtypes. His research has significantly contributed to the understanding and treatment of lymphomas, particularly in developing more personalized and effective treatment strategies. Scientific Awards: Faculty Academic Mentoring Award (2012) Scholar in Clinical Research (2008) America's Top Doctors Selection (2008) Jacob Gitelman Award (2007) Lawrence A. Kohn Senior Teaching Fellow (2004-2006) Clinical Investigator Career Development Award (2003) Clinical Oncology Research Fellowship "Immunotherapy of Hodgkin's Disease" (2001-2003) Rising stars program for innovative research (2001-2003) As Director of the Wilmot Cancer Institute, Dr. Friedberg leads numerous clinical trials and research initiatives focused on advancing lymphoma treatment. He is actively involved in SWOG and has served in leadership roles for multiple clinical trials investigating novel therapies for lymphoma patients. His practice team includes Anna Morrison, R.N., and Kerri Hugelmaier, N.P., providing comprehensive care for lymphoma patients. Dr. Friedberg has established the Lymphoma Epidemiology of Outcomes (LEO) Consortium, a large observational cohort study supporting broad research on NHL prognosis and survivorship. His leadership extends to national organizations where he contributes to developing clinical practice guidelines and consensus recommendations for lymphoma treatment.

Olga Dontsovaمشاهده پروفایل

استاد

• Molecular Biology
• Bioorganic Chemistry
• Ribonucleoprotein Complexes
• +۳ مورد دیگر

Olga Dontsova is a Full Professor at Moscow State University (MSU) in the Faculty of Chemistry. She serves as Head of the Division of RNA Structure and Function at the Belozersky Institute of Physico-Chemical Biology and Head of the Chair of Chemistry of Natural Compounds. Her research spans molecular biology, bioorganic chemistry, and RNA-based mechanisms. Research Focus: She investigates structure-functional relationships in ribonucleoprotein complexes, with emphasis on translation machinery, transfer-messenger RNA (tmRNA) interactions with ribosomes, RNA methyltransferases, and telomerase's role in cancer. Her team pioneered a chemical-biochemical-genetic approach to map mRNA topography in ribosomes, elucidate trans-translation dynamics, and characterize novel RNA-modifying enzymes. Scientific Contributions: Developed a molecular dynamic model for trans-translation Discovered unique yeast telomerase with unconventional properties Investigated functional roles of modified RNA residues in translation Honors: Member of Academia Europaea (2014) Corresponding Member of Russian Academy of Sciences (2006) European Academy Award for Young Scientists (1994) Grants & Leadership: Her work has been funded by HHMI, HFSP, CRDF, INTAS, RFFI, and Russian Ministry of Science and Education. She chairs the Biology Panel of the Russian Scientific Foundation and serves on editorial boards for Biochimie, Russian Journal of Molecular Biology, and Acta Naturae. Teaching: As a supervisor of 21 Ph.D. students and numerous diploma projects, she teaches advanced courses at MSU while maintaining an active research program.

• Fibrosis Research
• Liver Fibrosis
• Kidney Fibrosis
• +۹ مورد دیگر

Karen Piper Hanley is Professor of Molecular Medicine and Head of Division in the Division of Diabetes, Endocrinology & Gastroenterology at the University of Manchester. She serves as the fibrosis lead in the Wellcome Trust Centre for Cell-Matrix Research and previously served as Director of Core Research Technologies (2019-2022). She is also an editorial board member for Scientific Reports. Her research focuses on fibrosis (scarring) mechanisms across multiple organs, particularly liver, kidney, and lung fibrosis. Her lab investigates the cellular and molecular basis of fibrotic disease, with emphasis on how pathological scar components are produced and how they signal to surrounding cells. Key areas include the role of SOX9 transcription factor, integrin beta-1 signaling, Group 1 PAKs, and YAP1 in fibrosis progression. Her recent publications reveal trends toward increased clinical translation of fibrosis research, with studies on health inequalities in liver cancer care, post-COVID diabetes incidence, and innovative approaches to liver disease detection. Her work increasingly integrates spatial transcriptomics and advanced omics technologies to understand cellular transitions in liver disease. Career-track postdoctoral fellowship from the University of Southampton (2006) As senior postgraduate tutor, she has mentored numerous PhD students who have presented at key conferences and authored high-quality manuscripts. All her PhD students have submitted and been awarded their degrees within 4 years. She has successfully guided previous Academic Clinical Fellows to win MRC clinical training fellowships. Her teaching extends to undergraduate Personal & Professional Development and supervision of MRes and BSc students, many of whom have achieved first-class degrees and prestigious awards. Her lab maintains active collaborations with Professor Neil Hanley's group on human development, stem cells, and regenerative medicine, bridging developmental biology with fibrosis research to understand why regeneration is impaired in chronic diseases.

Alison Ledgerwoodمشاهده پروفایل

استاد

• Social Psychology
• Open Science
• Methodology
• +۴ مورد دیگر

Alison Ledgerwood is a Professor in the Department of Psychology at the University of California, Davis, and Principal Investigator of the Attitudes and Group Identity Lab. Her research examines how social context shapes attitudes and preferences, with a focus on open and inclusive scientific practices. Ph.D., Social Psychology, New York University (2008) M.A., Psychology, New York University (2006) B.A., Psychology, Amherst College (2003) Her research explores psychological distance , framing effects , and system justification theory , while methodologically advancing preregistration , collaborative science , and equity in publishing . She also investigates group identity dynamics and implicit/explicit bias measurement . Recent publications highlight her work on racial bias methodology , open science reform , and contextual framing . Awards include the 2024 Distinguished Service to the Society award, 2021 UC Davis Advising and Mentoring Award, and 2017 SPSP Service to the Field award. 2024 Distinguished Service to the Society, SPSP 2021 UC Davis Graduate Advising and Mentoring Award 2017 Service to the Field, SPSP Hellman Fellowship (2010-2011), UC Davis UC Davis Chancellor's Fellow APS Fellow SESP Fellow Ledgerwood advises on scientific integrity through roles like Chair of the Transparency and Openness Promotion (TOP) II Guidelines Task Force and Anti Colorism and Eurocentrism in Methods and Practices (ACEMAP) Task Force. Her lab fosters contextual evaluation studies and psychological distance frameworks .

Fahui Wangمشاهده پروفایل

استاد

• Spatially-Integrated Social Sciences
• Geographic Information Systems (GIS)
• Public Policy and Planning
• +۳ مورد دیگر

Fahui Wang is the Cyril & Tutta Vetter Alumni Professor in the Department of Geography & Anthropology at Louisiana State University (LSU). He holds a B.S. in Geography from Peking University (1988), an M.A. in Economics (1993), and a Ph.D. in City & Regional Planning (1995), both from The Ohio State University. His research focuses on spatially-integrated social sciences, public policy, and GIS applications in healthcare, urban planning, and public safety. He has authored/co-authored multiple influential books and peer-reviewed articles, including works on computational methods in GIS and healthcare accessibility analysis. Professor Wang’s work has been supported by grants from the National Institutes of Health, National Science Foundation, and U.S. Departments of Housing and Urban Development and Justice. His accolades include LSU’s Distinguished Research Master Award (2023) and CPGIS Distinguished Scholar (2023). He teaches advanced courses in GIS, urban geography, and quantitative methods, and leads research initiatives in the LSU Geoscience department. His lab focuses on geospatial technologies for addressing societal challenges in healthcare access, urban planning, and crime analysis.

Mark R. Pittelkowمشاهده پروفایل

استاد

• Dermatology
• Cutaneous Lymphomas
• Photoprotection
• +۳ مورد دیگر

Mark R. Pittelkow is a Professor of Dermatology at the Mayo Clinic, holding a primary appointment as a Consultant in the Department of Dermatology. He completed his MD at Mayo Medical School and advanced training through Mayo Graduate School of Medicine and Northwestern University. His research focuses on cutaneous lymphomas, photoprotection, and skin cancer, with leadership roles in international guidelines (ISCL/EORTC). He contributes to clinical trials, medical education, and interdisciplinary research through affiliations like the Mayo Clinic Comprehensive Cancer Center and Regenerative Biotherapeutics. Education: MD (Mayo Medical School), MS (Biological Sciences, Northwestern), BA (Northwestern University). Research spans cutaneous lymphoma classification, immunology, and translational dermatology. Notable publications address staging systems for mycosis fungoides/Sezary syndrome and photoprotection strategies. His work integrates clinical practice with molecular mechanisms, such as JAK inhibitor responses in lichen planus. Labs/Teams: Collaborates with Mayo Clinic Cancer Center and interdisciplinary groups in immunotherapy and regenerative medicine. Supervises clinical trials and postdoctoral training programs.

Andre Levchenkoمشاهده پروفایل

استاد

• Systems Biology
• Signal Transduction
• Cell Communication
• +۵ مورد دیگر

Andre Levchenko is the John C. Malone Professor of Biomedical Engineering at Yale University, with secondary appointments in the Department of Neurosurgery and affiliations with the Cancer Signaling Networks, Immunology, and the Yale Program in Neurodevelopment and Regeneration. His research focuses on systems biology, signal transduction, and cell-cell communication, utilizing microfluidics and computational modeling to study cancer progression, stem cell behavior, and neurological disorders. PhD, Columbia University MEng, Moscow Institute of Physics and Technology Levchenko's work explores how cells process dynamic signals to make critical decisions, particularly in glioblastoma migration, organoid development, and cardiovascular tissue engineering. His lab develops innovative microfluidic platforms and mathematical models to dissect multicellular communication and signaling networks. Recent publications highlight his contributions to understanding YAP-driven cancer invasion , NOTCH signaling in angiogenesis , and metabolic regulation of hypoxia responses . He has pioneered methods for organoid modeling and single-cell analysis , advancing precision in biological signaling studies. Scientific Awards : Computational Molecular Biology Post-Doctoral Fellowship (Burroughs Wellcome Fund) National Academies Keck Futures Conference Invitee Distinguished Guest Lecturer, University of Virginia American Asthma Foundation Early Excellence Award Fellow, American Institute for Medical and Biological Engineering Levchenko leads the Levchenko Lab at the Yale Systems Biology Institute, collaborating with institutions like Mayo Clinic and Yale Cancer Center. His research has received recognition in Faculty of 1000 and multiple journal highlights.

• Drug Delivery
• Nanomedicine
• Biopharmaceutics
• +۷ مورد دیگر

Dr. Shyh-Dar Li is a Professor and Tong Louie Chair in Pharmaceutical Sciences at the University of British Columbia's Faculty of Pharmaceutical Sciences, where he also serves as Chair of Nanomedicine and Chemical Biology. With a BSc in pharmacy from National Taiwan University (1998) and PhD in pharmaceutical sciences from UNC Chapel Hill (2008), followed by postdoctoral training at UC San Diego's Moores Cancer Center (2009), Dr. Li has established himself as a leading researcher in advanced drug delivery systems. His research focuses on developing innovative nanomedicine platforms for targeted delivery of biological therapeutics including peptides, proteins, antibodies, and nucleic acids. Dr. Li's laboratory has pioneered several novel drug delivery approaches, particularly in lipid-based nanoparticles, phospholipid-free vesicles, and polymer systems for cancer immunotherapy, pain management, and protein delivery. His work bridges fundamental nanotechnology with translational applications for difficult-to-treat diseases. Analysis of his recent publications reveals a strong emphasis on tumor microenvironment modulation, endosomal escape mechanisms for nucleic acid delivery, and non-invasive delivery routes for protein therapeutics. His research demonstrates increasing sophistication in nanocarrier engineering, with recent work incorporating machine learning approaches to optimize nanoparticle design and expanding into immunomodulatory therapies that harness the body's immune system to fight cancer. Scientific Recognition: 2014 AFPC New Investigator Award 2013 AAPS New Investigator Award in Pharmaceutics and Pharmaceutical Technologies 2013 CIHR New Investigator Award 2013 CSPS Early Career Award 2012 Prostate Cancer Foundation Young Investigator Award Dr. Li's research program has been consistently supported by major Canadian funding agencies including CIHR, NSERC, and MITACS. He actively collaborates across disciplines and accepts graduate students into his research program, focusing on cutting-edge approaches to overcome biological barriers in drug delivery. His laboratory, the Laboratory of Targeted Drug Delivery and Nanomedicine, serves as a hub for innovation in pharmaceutical nanotechnology.

Vikramaditya G. Yadavمشاهده پروفایل

دانشیار

• Biocatalysis
• Bioremediation
• Bioprocess engineering
• +۱۵ مورد دیگر

Vikramaditya G. Yadav is an Associate Professor at the University of British Columbia (UBC) in the Department of Chemical and Biological Engineering, Faculty of Applied Science. He directs the Master of Engineering Leadership (MEL) Program in Sustainable Process Engineering and leads the BioFoundry research group. Education: B.A.Sc., University of Waterloo (2007) Ph.D., Massachusetts Institute of Technology (2013) Postdoctoral Associate, Harvard University (2014) His research spans sustainable chemical manufacturing, metabolic engineering, and biotechnology. Key areas include: Designing biosynthetic enzymes for biomass valorization Developing bioremediation strategies for industrial water quality Creating innovative drug delivery systems and tissue engineering solutions Advancing synthetic biology for pharmaceutical and bioenergy applications His recent work focuses on ocular drug delivery, cannabinoid biosynthesis in E. coli, lignin-based nanoparticles for cancer therapy, and computational analysis of plant secondary metabolites. Collaborations with start-ups, industry, and medical labs drive innovation in Canada's bioeconomy. Professional Leadership: Chair, Biotechnology Division of the Chemical Institute of Canada Associate Editor, The Canadian Journal of Chemical Engineering He is affiliated with UBC's BioProducts Institute and contributes to project-based learning pedagogy.

James Briscoeمشاهده پروفایل

استاد

• Developmental Biology
• Molecular Signaling
• Transcriptional Networks
• +۴ مورد دیگر

James Briscoe is a Senior Group Leader at The Francis Crick Institute in London, where he leads a research group focused on developmental biology and morphogen signaling. He previously held positions at the Medical Research Council's National Institute for Medical Research, which later became part of the Francis Crick Institute. Education: BSc in Microbiology and Virology from the University of Warwick, UK PhD from Imperial Cancer Research Fund/King's College London Postdoctoral training at Columbia University with Thomas Jessell Dr. Briscoe's research focuses on the molecular and cellular mechanisms of graded signaling by morphogens and the role of transcriptional networks in cell fate specification. His laboratory employs a range of experimental and computational techniques using model systems including mouse and chick embryos and embryonic stem cells. His work has significant implications for understanding developmental processes and their relationship to disease. His recent publications demonstrate a continued focus on morphogen gradients, neural tube development, and computational approaches to understanding cell fate decisions. His research increasingly integrates single-cell technologies and computational modeling to unravel the complexities of developmental patterning. Scientific Awards and Honors: EMBO Young Investigator (2001) EMBO Gold Medal (2008) Elected to EMBO (2009) Fellow of the Academy of Medical Sciences (2019) Fellow of the Royal Society (2019) As Editor-in-Chief of the journal Development since 2018, Dr. Briscoe plays a significant role in shaping the field of developmental biology. His leadership extends to mentoring researchers and contributing to scientific policy discussions, as evidenced by his recent publication 'Science under siege: protecting scientific progress in turbulent times.' Dr. Briscoe's laboratory at the Crick Institute is well-equipped with access to advanced facilities including light microscopy, flow cytometry, genomics, and computational resources, enabling a multidisciplinary approach to developmental biology questions.

Kristian Helinمشاهده پروفایل

استاد

• Cancer biology
• Epigenetics
• Stem cells
• +۵ مورد دیگر

Kristian Helin is Chief Executive and President of The Institute of Cancer Research (ICR), London, and a Professor with affiliations at the University of Copenhagen and Memorial Sloan Kettering Cancer Center. He founded/directed the Biotech Research & Innovation Centre (BRIC), Centre for Epigenetics, and Danish Stem Cell Center. His research focuses on epigenetic regulation, cancer biology, and stem cell differentiation. Education: Ph.D. Molecular Biology, University of Copenhagen (1991) M.Sc. Chemical Engineering, Technical University of Denmark (1988) Research Interests: Helin's work deciphers molecular mechanisms in cancer, emphasizing epigenetic drivers (e.g., H3K4/H3K36 methylation), transcriptional control, and therapeutic targeting. His lab identified E2F transcription factors, linked epigenetic dysregulation to leukemia/lymphoma, and develops drugs targeting kinases/epigenetic enzymes. Research spans acute myeloid leukemia, B-cell lymphoma, and solid tumors using CRISPR screens and preclinical models. Publication Trends: Recent articles (2023-2025) focus on epigenetic therapy, chromatin remodeling, and kinase signaling in cancer. Key themes include targeting NSD1/KDM5C/RIOK2 enzymes, combination therapies (EZH2/DOT1L inhibitors), and metabolic regulation in leukemia. Studies bridge basic mechanisms (enhancer regulation, insulator accessibility) with translational applications. Awards: Anders Jahre Prize (2014), ERC Advanced Grant (2011), Novo Nordisk Prize (2008) Memberships: Academia Europaea, Royal Danish Academy, EMBO Leadership: Helin co-founded EpiTherapeutics (acquired by Gilead) and leads the Epigenetics and Cancer lab at ICR. His team investigates AML pathogenesis and chromatin complexes like HUSH/NURF. Grants include ERC funding and innovation prizes.